Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), discusses upcoming policy initiatives and the current oncology landscape amid a health care cyberattack.
The Community Oncology Alliance (COA) is aligned with keeping patient care in the hands of the community pharmacies and practices, and it is important that these organizations stick together to achieve the best quality of care, says Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, COA.
Transcript
On May 8, COA members and their patients will have an opportunity to meet with their members of Congress and their staff to discuss bills that make it easier to access cancer care. Can you tell us what COA’s priorities will be for this day?
Yes. So, the Stark law will be a priority for our Hill day on May 8, as well as PBM [pharmacy benefit manager] bills that are currently being looked at. We really want to keep patient care in the hands of their community pharmacies and their community practice. So, we'll be educating those in Congress and on the Hill on what the Stark law is, what kind of impact that has, and hopefully we'll have patients with us who can talk firsthand to their struggles and what they're experiencing.
Where does COA stand on the Change Healthcare cyberattack right now?
We've been really hitting this hard with all our representatives. We've been in Washington, DC, we've been having discussions with CMS, we've been reaching out to individual MACs [Medicare administrative contractors] to make sure that they are affording practices the time and the resources that they need to recover from this. Whether it's switching MACs, whether it's extensions and different kinds of reimbursements in their claims, really having the support of GPOs [group purchasing organizations], the government, and everybody who's involved in this claim processing, to just give a little bit of leeway to these practices while they struggle with their resources to still be able to provide while they're not getting reimbursed on their claims.
Just in general, I think that the whole theme of this conference is [we're] stronger together. And really in all the questions that we've talked about today, we're stronger together. So as a team-based approach with the patient in the middle of care is how we can accomplish overcoming cancer and making the journey for the cancer patient more accessible, and just a better overall experience with high-quality cancer care.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More